Loading, Please Wait...
Receives five new patents across strategic areas including biocatalytic manufacturing processes, generation of new chemical entities (NCEs) and cannabinoid formulations
Proprietary CannSynthesis® technology platform is the world’s only patent protected biocatalytic process for the production of cannabinoids
TAMPA, Fla., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid analogs as new chemical entities, today announced the issuance of multiple patents covering features of the Company’s CannSynthesis technology platform. Currently, Teewinot has 18 issued and allowed patents with over 40 patent applications pending in key global markets. Teewinot’s IP portfolio includes patents with claims around composition of matter, methods of manufacture, formulations and the use of cannabinoids.
The Teewinot patent portfolio provides comprehensive protection of its CannSynthesis technology platform that supports its drug development pipeline, while also strategically supplying the growing global demand for cGMP cannabinoids in the pharmaceutical, nutraceutical, and consumer health markets.
“The addition of these new patents further strengthens our position as the leader in the biosynthetic cannabinoid space utilizing our proprietary CannSynthesis platform,” stated Dr. Michael Luther, Chief Executive Officer. “This commercially scalable process, which can achieve production levels of up to 180 grams per liter, has allowed us to create a diverse range of cannabinoids including minor cannabinoids and analogs. These capabilities clearly distinguish Teewinot from other cannabinoid companies and provide us with a first-mover advantage in cannabinoid research and evidence-based science for drug and product development. We believe our capabilities make us the partner of choice for companies looking to access consistent, high quality, pharmaceutical grade cannabinoids for underserved health, wellness, and therapeutic applications.”
New patents around the CannSynthesis cannabinoid production platform include:
New patents around NCE composition of matter and enhanced cannabinoid formulation include:
“The issuance of these additional patents reflects the many unique features of our CannSynthesis platform and its potential to create new chemical entities to further our drug development programs,” added Dr. Steve Orndorff, Chief Operating Officer. “With CannSynthesis, we can recognize the enormous potential of cannabinoids and their analogs in the development of new therapeutic agents to address unmet medical needs.”
CannSynthesis® is the world’s only patent-protected biocatalytic process for the production of rare cannabinoids from bench to cGMP commercial scale. It utilizes a modular approach for bioreactions to produce specific rare cannabinoids at high titer and purity with high efficiency and speed. The biocatalytic process is complemented with a variety of proprietary chemical transformations to convert the biologically-derived cannabinoids into other rare cannabinoids. Today, this platform allows for Teewinot to deliver the widest and most diverse range of cannabinoids for the growing market demand.
About Teewinot Life Sciences
Teewinot Life Sciences is a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. The Company is leveraging a unique integrated biocatalytic and chemical synthesis platform, that allows the production of an unprecedented range of cannabinoids and cannabinoid NCEs from bench to cGMP manufacturing. This platform supports Teewinot’s drug discovery programs as well as industry partnerships for pharmaceutical and consumer product development. Teewinot is revolutionizing the synthetic cannabinoid space with its cost-effective, commercial scale approach to meet the global growing demand for cannabinoid-based products to address unmet health, wellness, and therapeutic needs.
Forward Looking Statements
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward- looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, ultimate clinical outcomes and benefit of the Company’s products, market acceptance of the Company’s products, intellectual property protection, competitive product offerings, adverse changes in the public perception of cannabis, adverse changes in applicable laws and adverse changes in the application or enforcement of current laws, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise.
LifeSci Advisors, LLC